论文部分内容阅读
目的:探讨卡介苗/纯蛋白衍生物治疗儿童哮喘的临床效果。方法:选取2007年1月～2010年10月治疗的78例小儿哮喘患者为研究对象,将其随机分为对照组(常规治疗组)39例和观察组(常规治疗加卡介苗/纯蛋白衍生物组)39例,对两组患儿的控制效果及治疗前后的外周血T淋巴细胞亚群和肺功能进行检测及比较。结果:观察组的总有效率高于对照组,CD3+、CD4+和CD4+/CD8+高于对照组,CD8+低于对照组,肺功能各项指标改善幅度大于对照组,差异均有统计学意义(P<0.05)。结论:卡介苗/纯蛋白衍生物在控制儿童哮喘中的效果明显,可显著改善患儿的免疫状态及肺功能。
Objective: To investigate the clinical efficacy of BCG / NP derivatives in children with asthma. Methods: A total of 78 children with asthma treated from January 2007 to October 2010 were enrolled in this study. They were randomly divided into control group (conventional treatment group) and observation group (conventional treatment plus BCG / neat protein derivative Group) 39 cases, the control effect of two groups of children and before and after treatment of peripheral blood T lymphocyte subsets and lung function were detected and compared. Results: The total effective rate in the observation group was higher than that in the control group, CD3 +, CD4 + and CD4 + / CD8 + were higher than those in the control group, and CD8 + was lower than that in the control group. The indexes of lung function improvement were significantly higher than those in the control group <0.05). CONCLUSION: BCG / NP derivatives are effective in controlling childhood asthma and can significantly improve children’s immune status and lung function.